Abdominal Aortic Aneurysm Clinical Trial
Official title:
The Inter and Intra Reliability of Cardiopulmonary Exercise Testing in Abdominal Aortic Aneurysm Patients
Exercise testing is commonly being used in patients before surgery to test their overall fitness. One group it is being used in is patients who have an enlarged blood vessel in their stomach. This is known as an abdominal aortic aneurysm. The exercise test used is known as a cardiopulmonary exercise test as it looks at both heart and lung function at the same time. Whilst this test is commonly used there have been no studies (to date) which have looked at how reliable this test is; this means how well the investigators can obtain the same (or very similar) results after multiple tests. The investigators would like to test this reliability both between patients and the clinicians performing the testing.
Background Research:
The definition of an 'aneurysm' is permanent, localised dilatation of a blood vessel or heart
chamber. The abdominal aorta is the largest blood vessel in the human body and usually has a
diameter of 1.8 -2.0 centimetres (cm), dependant on age, sex and body habitus. Aortic
dilatation is generally classed as an 'aneurysm' when dilation of the vessel is 1.5 times the
normal size. An abdominal aortic aneurysm (AAA) affects any part of the aorta below the
diaphragm with 80 % typically being found between the renal artery and aortic bifurcation.
Risk Factors There are many factors that relate to the development of AAA. Gender is one of
the biggest non-modifiable risk factors, as an AAA is four to six times more likely in males
compared with females. Furthermore, the development of AAA in females occurs approximately
ten years later than males. The risk of AAA also increases if there is family history of the
disease, especially if the relative is first degree. There is also evidence to suggest there
is an association between AAA and coronary heart disease. Hypertension has also been found to
closely correlate with the development of AAA. Additionally, there is also a strong link
between smoking and the likelihood of AAA development. Conversely, whilst the risk of AAA
development in women is less than men, women have been shown to be more vulnerable to
developing AAA than their male counterparts. The risk of AAA's also increases after the age
of 65 years.
If AAA are left undetected or untreated there is an increase in the likelihood of a rupture
occurring. This causes critical internal bleeding and often results in death. Rupture of AAA
is the cause of approximately 6000 deaths per year in the United Kingdom. Figures between
1997- 2005 have shown a decrease in mortality but this is due to an earlier detection (of
around five to ten years). The likelihood of rupture increases due to age, sex, smoking,
hypertension and size and growth rate of the aneurysm. The size of the aneurysm is the
strongest predictor of risk of rupture, smoking also contributes to an acceleration in
expansion rate.
Ultrasound Screening:
Ultrasound screening is the preferred tool in identifying and monitoring the development of
AAA as it is highly sensitive, cost effective and a non-invasive tool. The National Institute
of Clinical Excellence (NICE) guidelines recommend that the National Health Service (NHS)
offers ultra-sonographic screening to all males age 65 or over. The ultrasound scan enables
the medical screener to determine the size of the abdominal aorta. According to the NICE
(1.3) guidelines AAA are categorised by size, with a diameter of less than three cm being
classified as normal with no follow up required. Patients who have an aneurysm diameter of
between 3- 4.4 cm are re-scanned yearly, with those between 4.5 -5.4 cm being rescanned
quarterly (every three months). AAA patients who have a diameter greater than 5.4 cm are
referred to a vascular consultant for diagnosis and treatment. An AAA can be either true or
false, with true aneurysms more commonly found. True aneurysms; involve three layers of the
blood vessel walls Intima, Media and Adventitia, whereas false aneurysms are essentially a
haematoma that forms outside the vessel wall.
Surgical management of AAA:
Following the diagnosis of a large AAA there are two possible medical surgical interventions,
open or endovascular repair (EVAR).Open repair is considered to be a major surgical procedure
and because of the possible complications preoperative assessment has to be carefully
managed. There are three approaches whilst performing AAA laparotomy, transverse incision,
longitude midline incision and retroperitoneal approach. The aortic segment is replaced by a
prosthetic graft. After the operation patients are often monitored in intensive care unit
(ICU) on average remain in hospital between seven to fourteen days. EVAR on the other hand is
less invasive procedure, less painful and has a shorter stay in hospital and often does not
require stay in ICU. EVAR gains access though the femoral artery and inserts a sent graft
inside the abdominal aneurysm.
Preoperative Risk Management:
Surgeons base the decisions for operating on two major factors, firstly the risk of rupture,
and secondly the diameter of the aneurysm and the growth rate. Before surgery the vascular
consultant will subject the patient to a preoperative functional capacity assessment (FCA).
The surgeons use FCA to establish if there are any potential operative and postoperative
risks. Patients often have other comorbidities so the risk of operating may outweigh the
potential benefits, therefore increasing the risk of premature mortality. The use of FCA has
become an important screening tool in evaluating the fitness of AAA patients, serving as a
good indictor to the risk of surgery and postoperative recovery. There are various ways to
test FCA (step test, spirometry and cardiopulmonary exercise testing etc.) however, more
recently cardiopulmonary exercise testing has been described as preferable tool in evaluating
AAA patient's functional capacity.
Cardio pulmonary exercise testing:
It is widely accepted that a cardio-pulmonary exercise test (CPEX) is the 'gold standard' of
FCA. Furthermore, CPEX is a non-invasive, cost effective and objective. It has been used for
many years in elite sporting performance for research and screening and is now becoming
increasingly utilised in clinical environments. CPEX testing allows clinicians to perform a
controlled exercise test in a safe environment. It involves the measurement of a number of
physiological parameters, as well as respiratory and cardiac monitoring.The basic underlying
physiological principles underlying a CPEX is that it measures the efficiency and capacity of
the oxygen-transport system; it also examines an individual's ability to exercise and the
cardiovascular responses to variable levels of exertion. A CPEX provides breath by breath
analysis and provides several important outcomes. These are; (1) VO2 MAX, (2) VeO2, (3)
VECO2, (4)anaerobic threshold (AT), (5) respiratory exchange ratio, (6) time to AT and (7)
total time tolerated are the variables that are obtained.
Anaerobic threshold (AT):
At the beginning of exercise, adenosine trisphosphate-creatine phosphate provides immediate
energy required by the working muscles. As exercise continues cardiac output increases
providing the working muscles with increased blood flow. As exercise levels rise, the
workload of the muscles also rises requiring more blood flow and oxygen to be delivered. The
oxygen demand is met by an increase cardiac output and lung ventilation. As the exercise
continuous to become more strenuous, the muscle demand will begin to exceed the rate of
oxygen delivery by the respiratory system. At this point the main fuel glucose is metabolised
into lactic acid. This dissociates to lactate and hydrogen ions (H+) resulting in acidosis,
which is the marker known as the Anaerobic Threshold (AT). The most common way of measuring
the AT non-invasively is the V-slope method see figure 1.
This can be explained via the following:
As a participant begins incremental exercise their expired minute volume (VE) increases
linearly with their oxygen consumption (VO2) and carbon dioxide consumption (VCO2). H+ are
produced via anaerobic metabolism which is buffered by bicarbonate (HCO3-) and produces
carbon dioxide (CO2). This is washed out in the lungs and is measured via the breath by
breath analysis in the expired air. As VCO2 rises disproportionately to VO2, it allows the
clinician to determine the AT; this is achieved by plotting VCO2 against VO2. Linear
regression lines are drawn through the upper and lower curve and the point of intersection
indicates where VCO2 increased disproportionately to VO2 and hence is estimated to be the AT.
An individual's aerobic capacity is known as their VO2MAX. The most common way of measuring a
person VO2 max is an incremental exercise test either performed on a motorized treadmill or
cycle-ergometer, measured in millilitres per kilogram per minute (ml.kg.min). The aerobic
capacity can be affected by factors such as gender, genetics, body composition and age. A
healthy 20-25 year old male has an average VO2 max of 42.5 - 46.4 ml.kg.min, whereas a
healthy female of the same age has an average of 33 - 36.9 ml.kg.min. There is approximately
ten percent drop with aerobic capacity every decade (dependent on fitness). For patients with
AAA it is suggested that they should achieve and a threshold (AT) value above 10.2 ml.kg.min
for open repair or above 8.2 for EVAR. They should also achieve a VO2MAX value above 15
ml.kg.min. Values lower than this can increase the risk of postoperative mortality (within 30
days).
Whilst there have been numerous studies into the importance of a CPEX, there have been no
studies to date which have determined the Inter and Intra reliability of this test in the AAA
population.
Aim:
The aim of this study is therefore to determine the Inter and Intra reliability of CPEX
testing on both a cycle- ergometer and motorised treadmill in patients with abdominal aortic
aneurysms.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04227054 -
Abdominal Aortic Aneurysm Sac Healing and Prevention of Endoleaks
|
N/A | |
Active, not recruiting |
NCT03687489 -
Safety and Efficacy Study of Abdominal Aortic Aneurysm Stent Graft System
|
N/A | |
Active, not recruiting |
NCT03507413 -
Metformin Therapy in Non-diabetic AAA Patients
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT05756283 -
The PREHAAAB Trial: Multimodal Prehabilitation for Patients Awaiting Open Abdominal Aortic Aneurysm Repair
|
N/A | |
Not yet recruiting |
NCT04089241 -
Fusion of CT Angiography With 3D Contrast Ultrasound as a Method for Follow up for Endovascular Aneurysm Repair
|
N/A | |
Active, not recruiting |
NCT02604303 -
A Prospective Analysis on the Expansion Rates of Abdominal Aortic Aneurysms
|
||
Terminated |
NCT01843335 -
Contrast-enhanced Ultrasound in Follow-up After Endovascular Aneurysm Repair
|
N/A | |
Completed |
NCT02224794 -
LIFE Study: Least Invasive Fast-Track EVAR
|
||
Terminated |
NCT02469376 -
Evaluation of a New Imagingtechnologie for Thrombosis
|
Phase 1 | |
Completed |
NCT02229006 -
Sodium Fluoride Imaging of Abdominal Aortic Aneurysms
|
N/A | |
Terminated |
NCT01425242 -
Study on Anti-inflammatory Effect of Anti-hypertensive Treatment in Patients With Small AAA's and Mild Hypertension
|
N/A | |
Completed |
NCT01118520 -
AARDVARK (Aortic Aneurysmal Regression of Dilation: Value of ACE-Inhibition on RisK)
|
Phase 2 | |
Completed |
NCT00746122 -
Immediate Management of the Patient With Rupture : Open Versus Endovascular Repair
|
N/A | |
Completed |
NCT03952780 -
Korean Registry of Percutaneous EVAR With INCRAFT Stent Graft for the Treatment of Abdominalaortic Aneurysm (K-INCRAFT)
|
||
Completed |
NCT00583414 -
Endovascular Exclusion of Abdominal Aortic Aneurysms in High Risk Patients
|
N/A | |
Recruiting |
NCT05864560 -
Ankura™ AAA, Cuff and AUI Stent Graft System Post-Market Clinical Follow-Up
|
||
Completed |
NCT01683084 -
Study of the Effectiveness of Telmisartan in Slowing the Progression of Abdominal Aortic Aneurysms
|
Phase 4 | |
Active, not recruiting |
NCT03180996 -
Global Fenestrated Anaconda Clinical sTudy
|
||
Completed |
NCT02493296 -
The Effect of Surgery on Central Aortic Pressure & haEmodynamics Study
|
||
Completed |
NCT03320408 -
Predicting Aneurysm Growth and Rupture With Longitudinal Biomarkers
|